Ray Dalio’s IONS Holdings & Trades

First Buy
Q2 2021
Duration Held
18 Quarters
Largest Add
Q3 2025
+43,578 Shares
Current Position
43,578 Shares
$2.85 M Value

Ray Dalio's IONS Position Overview

Ray Dalio (via Bridgewater Associates, Lp) currently holds 43,578 shares of Ionis Pharmaceuticals, Inc. (IONS) worth $2.85 M, representing 0.01% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 18 quarters.

Based on 13F filings, Ray Dalio has maintained a strategic position in IONS, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 33,799 shares. Largest reduction occurred in Q1 2022, reducing 780 shares.

Analysis based on 13F filings available since 2013 Q2

Ray Dalio's Ionis Pharmaceuticals (IONS) Holding Value Over Time

Track share changes against reported price movement

Quarterly Ionis Pharmaceuticals (IONS) Trades by Ray Dalio

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2021 +7,981 New Buy 7,981 $39.84
Q3 2021 -7,981 Sold Out 7,981 $0.00
Q1 2022 +7,201 New Buy 7,201 $37.08
Q2 2022 +2,578 Add 35.80% 9,779 $37.02
Q3 2022 -9,779 Sold Out 9,779 $0.00
Q3 2025 +43,578 New Buy 43,578 $65.42

Ray Dalio's Ionis Pharmaceuticals Investment FAQs

Ray Dalio first purchased Ionis Pharmaceuticals, Inc. (IONS) in Q2 2021, acquiring 7,981 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ray Dalio has held Ionis Pharmaceuticals, Inc. (IONS) for 18 quarters since Q2 2021. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ray Dalio's largest addition to Ionis Pharmaceuticals, Inc. (IONS) was in Q3 2025, adding 43,578 shares worth $2.85 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 43,578 shares of Ionis Pharmaceuticals, Inc. (IONS), valued at approximately $2.85 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, Ionis Pharmaceuticals, Inc. (IONS) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ray Dalio's peak holding in Ionis Pharmaceuticals, Inc. (IONS) was 43,578 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.